Bengaluru-based Biocon Ltd. reported a 56.7 per cent decline in consolidated profit to ₹135.5 crore in Q4 FY24 compared to ₹313.2 crore in Q4 FY23. Additionally, consolidated profit fell by 79.7 per cent quarter-on-quarter (q-o-q) from ₹660 crore in Q3 FY24.
The revenue from operations grew by 3.7 per cent year-on-year (y-o-y) to ₹3,917.1 crore in Q4 FY24 from ₹3,773.9 crore in Q4 2023 and declined by 0.9 per cent q-o-q from ₹3,953.7 crore in Q3 2024.
Earnings before interest, tax, depreciation and amortisation (EBITDA) for Q4 FY24 stood at ₹964 crore, with an EBITDA margin of 24 per cent. The Board of Directors has recommended a final dividend of ₹0.50 per share at the rate of 10 per cent of the face value of the share, for the financial year ended March 31, 2024.
Also read: Zoho’s Sridhar Vembu could foray into semiconductor market with an investment of $700 million
The shares closed at ₹305.90 down by 1.81 per cent at the end of trading hours before the results were declared, compared to broader Sensex which closed by ₹73,663.72 up by 0.93 per cent.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said, “Q4FY24 performance was strongly led by Biologics that delivered the promised billion-dollar annual revenue milestone marking the successful transition of the Biosimilars acquisition from Viatris.”
“For the full year FY24, we reported consolidated revenue growth of 35 per cent at ₹15,621 crore and an EBITDA growth of 44 per cent at ₹4,164 crore with healthy EBITDA margins of 27 per cent This growth was largely driven by biosimilars which grew 58 per cent to ₹8,824 crore. The Biocon Group has strengthened business operations, expanded global reach and is now increasingly well positioned to deliver a new phase of growth spanning biosimilars, GLP-1 peptides and CDMO services,” she added.
(Inputs from bl intern Vidushi Nautiyal)
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.